期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 56, 期 17, 页码 6945-6953出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm400769b
关键词
-
资金
- Medical Research Council (MRC)/Canadian [G1100135]
- Biotechnology, and Biological Sciences Research Council (BBSRC)
- Cancer Research UK (CRUK)
- MRC
- BBSRC
- Medical Research Council [MR/K018779/1, G1100135] Funding Source: researchfish
- MRC [G1100135, MR/K018779/1] Funding Source: UKRI
Metallo-beta-lactamases (MBLs) are a growing threat to the use of almost all clinically used beta-lactam antibiotics. The identification of broad-spectrum MBL inhibitors is hampered by the lack of a suitable screening platform, consisting of appropriate substrates and a set of clinically relevant MBLs. We report procedures for the preparation of a set of clinically relevant metallo-beta-lactamases (i.e., NDM-1 (New Delhi MBL), IMP-1 (Imipenemase), SPM-1 (Sao Paulo MBL), and VIM-2 (Verona integron-encoded MBL)) and the identification of suitable fluorogenic substrates (umbelliferone-derived cephalosporins). The fluorogenic substrates were compared to chromogenic,substrates (CENTA, nitrocefin, and imipenem), showing improved sensitivity and kinetic parameters. The efficiency of the fluorogenic substrates was exemplified by inhibitor screening, identifying 4- chloroisoquinolinols as potential pan MBL inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据